[go: up one dir, main page]

MX2022013657A - Quimioterápicos de éter macrocíclico heteroaromático. - Google Patents

Quimioterápicos de éter macrocíclico heteroaromático.

Info

Publication number
MX2022013657A
MX2022013657A MX2022013657A MX2022013657A MX2022013657A MX 2022013657 A MX2022013657 A MX 2022013657A MX 2022013657 A MX2022013657 A MX 2022013657A MX 2022013657 A MX2022013657 A MX 2022013657A MX 2022013657 A MX2022013657 A MX 2022013657A
Authority
MX
Mexico
Prior art keywords
heteroaromatic
chemotherapeutic agents
macrocyclic ether
compounds
macrocyclic
Prior art date
Application number
MX2022013657A
Other languages
English (en)
Inventor
Joshua Courtney Horan
Xinxing Tang
Henry Efrem Pelish
Matthew D Shair
Scot Richard Mente
Anupong Tangpeerachaikul
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of MX2022013657A publication Critical patent/MX2022013657A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos de éter macrocíclico heteroaromático heterocíclicos, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos. La descripción se refiere además a métodos para tratar o prevenir el cáncer usando los compuestos de éter macrocíclico heteroaromático heterocíclicos, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos.
MX2022013657A 2020-05-05 2021-05-05 Quimioterápicos de éter macrocíclico heteroaromático. MX2022013657A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020088590 2020-05-05
US202063125733P 2020-12-15 2020-12-15
PCT/US2021/030842 WO2021226208A2 (en) 2020-05-05 2021-05-05 Heteroaromatic macrocyclic ether chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MX2022013657A true MX2022013657A (es) 2023-02-01

Family

ID=78468784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013657A MX2022013657A (es) 2020-05-05 2021-05-05 Quimioterápicos de éter macrocíclico heteroaromático.

Country Status (13)

Country Link
US (3) US11542278B1 (es)
EP (1) EP4146626A4 (es)
JP (1) JP7519463B2 (es)
KR (2) KR102699528B1 (es)
CN (1) CN115916754A (es)
AU (1) AU2021268664A1 (es)
BR (1) BR112022022535A2 (es)
CA (1) CA3179700A1 (es)
CL (1) CL2022003045A1 (es)
IL (1) IL297832A (es)
MX (1) MX2022013657A (es)
PE (1) PE20230608A1 (es)
WO (1) WO2021226208A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297898A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
KR102868758B1 (ko) 2021-04-13 2025-10-14 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클
IL311387A (en) * 2021-10-01 2024-05-01 Nuvalent Inc Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023056405A1 (en) * 2021-10-01 2023-04-06 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023179600A1 (zh) * 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
EP4568969A1 (en) 2022-08-12 2025-06-18 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途
WO2025072120A1 (en) 2023-09-25 2025-04-03 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds
WO2025131085A1 (zh) * 2023-12-22 2025-06-26 首药控股(北京)股份有限公司 一种新型激酶抑制剂
WO2025212478A1 (en) 2024-04-01 2025-10-09 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS60243083A (ja) 1984-05-18 1985-12-03 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体、その製法および該誘導体を含有する除草剤
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP0999825B1 (en) 1997-07-29 2003-10-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE60121990T2 (de) 2000-12-20 2007-03-08 Kyowa Hakko Chemical Co., Ltd. Squaryliumverbindungen vom metallkomplex-typ sowie optische aufzeichnungsmedien hergestellt unter verwendung derselben
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
EP2325225B2 (en) 2002-10-30 2019-12-11 Sumitomo Chemical Company, Limited Complex aryl copolymer compounds and polymer light emitting devices made by using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7446211B2 (en) 2004-04-27 2008-11-04 Wyeth Coupling process for generating reactive boron-containing derivatives of N-substituted pyrrole-2-carbonitriles to produce biaryls
CN1953967B (zh) 2004-04-27 2013-03-13 惠氏公司 孕酮受体调节剂的纯化
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006034090A1 (en) 2004-09-20 2006-03-30 Janssen Pharmaceutica N.V. Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
CA2642583C (en) 2006-02-16 2016-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
GB0603891D0 (en) 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
CN101687865A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 稠合的苯并咪唑和氮杂苯并咪唑的区域选择性金属催化合成
MX2010000130A (es) 2007-07-02 2010-03-18 Astrazeneca Ab Derivados de 3-espiropirimidintriona-quinolina y su uso como agentes antibacterianos.
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
EP2564857B1 (en) 2008-03-06 2017-05-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
WO2011016582A1 (ja) 2009-08-04 2011-02-10 株式会社トクヤマ クロメン化合物
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
US8410091B1 (en) 2009-09-11 2013-04-02 Boehringer Ingelheim International Gmbh Process for preparation of substituted 2-amino-5-(5-(heterocyclemethyl)pyridin-2-yloxy)benzoic acid
CA2774266A1 (en) 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
EP2598510A4 (en) 2010-07-30 2014-02-26 Reddys Lab Ltd Dr LIGANDS FOR SELECTIVE ASYMMETRIC HYDROFORMYLATION
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
CN103228660A (zh) 2010-12-01 2013-07-31 辉瑞大药厂 Kat ii 抑制剂
WO2012085222A1 (en) 2010-12-22 2012-06-28 Universite Catholique De Louvain Novel phenazine derivatives and their use
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
AU2012209701A1 (en) 2011-01-27 2013-07-25 Tokuyama Corporation Chromene compound
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
CN102408385B (zh) 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
CN102977150B (zh) 2011-09-06 2016-07-06 郑建鸿 含有碳烯配位基的过渡金属错合物结构及其在发光材料的应用
JPWO2013125543A1 (ja) 2012-02-20 2015-07-30 武田薬品工業株式会社 複素環化合物
CN102603659B (zh) 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
JP6199752B2 (ja) 2013-01-24 2017-09-20 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子、並びに含窒素複素環化合物
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
ES2656189T3 (es) 2013-06-28 2018-02-26 Pfizer Inc. Formas sólidas de un inhibidor macrocíclico de quinasa
EP3036231B1 (en) 2013-08-22 2020-02-26 Jubilant Biosys Ltd. Substituted pyrimidine compounds, compositions and medicinal applications thereof
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
HRP20210431T1 (hr) 2013-11-18 2021-05-14 Forma Therapeutics, Inc. Pripravci tetrahidrokinolina kao inhibitori bet bromodomene
US20160256448A1 (en) 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
ES2902835T3 (es) 2014-01-09 2022-03-30 Hadasit Med Res Service Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105585534B (zh) 2014-10-23 2018-05-18 上海雅本化学有限公司 一种1-取代-1h-1,2,3-三氮唑-4-羧酸的制备方法
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
FI3247707T3 (fi) 2015-01-22 2023-08-22 Myokardia Inc Sydänhäiriöiden kuten dilatoivan kardiomyopatian (dcm) hoitoon hyödyllisiä 4-metyylisulfonyylisubstituoituja piperidiiniureayhdisteitä
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
JP6811233B2 (ja) 2015-08-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｎｆアルファの修飾因子として有用な環状化合物
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
JP7100362B2 (ja) 2015-11-13 2022-07-13 ドメイン・セラピューティクス グループｉｉ代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換三環式１，４－ベンゾジアゼピノン誘導体
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
CN105669733A (zh) 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法
EP3763693A1 (en) 2016-03-03 2021-01-13 Shenzhen TargetRx, Inc. Macrocycle and composition comprising thereof
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
CN110072859B (zh) 2016-12-13 2022-10-11 勃林格殷格翰国际有限公司 作为RORγ调节剂的化合物
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
WO2019113071A1 (en) 2017-12-05 2019-06-13 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating alk-mediated cancer
WO2019120263A1 (zh) 2017-12-21 2019-06-27 广州华睿光电材料有限公司 有机混合物及其在有机电子器件中的应用
WO2019149131A1 (zh) * 2018-01-30 2019-08-08 上海吉倍生物技术有限公司 具有大环分子结构的化合物及其用途
CN113999277B (zh) 2018-02-11 2023-08-29 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
WO2019164301A1 (ko) 2018-02-21 2019-08-29 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
EP3827003A1 (en) 2018-07-26 2021-06-02 Enterome Process for preparing mannose derivatives
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
US12233128B2 (en) 2018-09-27 2025-02-25 Dana-Farber Cancer Institute, Inc. Degraders that target ALK and therapeutic uses thereof
KR102858043B1 (ko) 2018-10-30 2025-09-10 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
WO2020228747A1 (en) 2019-05-14 2020-11-19 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
US20220298130A1 (en) 2019-08-02 2022-09-22 Duk San Neolux Co., Ltd. Organic electronic device
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
WO2021057882A1 (zh) 2019-09-26 2021-04-01 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
US20230027026A1 (en) 2019-09-27 2023-01-26 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
CN110734456A (zh) 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
US12442787B2 (en) 2019-12-16 2025-10-14 I-Sens, Inc. Transition metal electron transfer complex having C—N ligand and electrochemical bio sensor using same
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
JP7688042B2 (ja) 2020-03-30 2025-06-03 ハチメド リミテッド アミド化合物およびその使用
CN111440154B (zh) 2020-04-24 2022-04-19 梯尔希（南京）药物研发有限公司 一种替格列汀二聚体杂质的合成方法
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
IL297898A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
CR20220561A (es) 2020-05-06 2023-02-17 Servier Lab Nuevos inhibidores macrocíclicos de la quinasa de lrrk2
US20230174554A1 (en) 2020-05-18 2023-06-08 Shenzhen TargetRx. Inc. Solid form of macrocyclic compound, preparation therefor and use thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
WO2022017408A1 (zh) 2020-07-22 2022-01-27 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
WO2022175747A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US11814367B2 (en) 2021-03-15 2023-11-14 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof
WO2022212538A1 (en) 2021-03-31 2022-10-06 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用
US12503454B2 (en) 2021-05-13 2025-12-23 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2022241171A1 (en) 2021-05-14 2022-11-17 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2023056405A1 (en) 2021-10-01 2023-04-06 Nuvalent, Inc. Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
IL311387A (en) 2021-10-01 2024-05-01 Nuvalent Inc Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023059801A1 (en) 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
WO2023179600A1 (zh) 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
TW202400608A (zh) 2022-04-07 2024-01-01 美商努法倫特公司 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備

Also Published As

Publication number Publication date
AU2021268664A1 (en) 2022-10-20
BR112022022535A2 (pt) 2023-04-25
JP2023525038A (ja) 2023-06-14
CL2022003045A1 (es) 2023-10-06
WO2021226208A2 (en) 2021-11-11
KR20240132391A (ko) 2024-09-03
US20240352037A1 (en) 2024-10-24
EP4146626A2 (en) 2023-03-15
EP4146626A4 (en) 2024-05-29
WO2021226208A3 (en) 2021-12-16
JP7519463B2 (ja) 2024-07-19
KR20230019833A (ko) 2023-02-09
PE20230608A1 (es) 2023-04-13
KR102699528B1 (ko) 2024-08-30
US11542278B1 (en) 2023-01-03
CN115916754A (zh) 2023-04-04
JP2024138377A (ja) 2024-10-08
CA3179700A1 (en) 2021-11-11
US12054498B2 (en) 2024-08-06
US20230107663A1 (en) 2023-04-06
IL297832A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2022013657A (es) Quimioterápicos de éter macrocíclico heteroaromático.
PH12022552787A1 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MX2023012060A (es) Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020551305A1 (en) Pharmaceutical Compounds
EP4520328A3 (en) Heterocyclic compounds as immunomodulators
PH12022552739A1 (en) Fused tricyclic kras inhibitors
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
PH12019501639B1 (en) Jak1 selective inhibitors
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
MX2024013838A (es) Compuestos y usos de estos
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2021010321A (es) Compuestos macrociclicos.
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
MX2021007247A (es) Derivados de rapamicina.
MX2020011089A (es) Compuestos antiproliferacion y usos de los mismos.
PH12021553177A1 (en) Pharmaceutical composition for treating tumor
MX2025004213A (es) Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
GEAP202516749A (en) Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
PH12021550323A1 (en) Dendrimer formulations